Factor H (FH) is an abundant serum glycoprotein that regulates the alternative pathway of complement-preventing uncontrolled plasma C3 activation and nonspecifi c damage to host tissues. Age-related macular degeneration (AMD), atypical hemolytic uremic syndrome (aHUS), and membranoproliferative glomerulonephritis type II (MPGN2) are associated with polymorphisms or mutations in the FH gene (Cf h), suggesting the existence of a genotypephenotype relationship. Although AMD and MPGN2 share pathological similarities with the accumulation of complement-containing debris within the eye and kidney, respectively, aHUS is characterized by renal endothelial injury. This pathological distinction was refl ected in our Cf h association analysis, which demonstrated that although AMD and MPGN2 share a Cf h at-risk haplotype, the haplotype for aHUS was unique. FH-defi cient mice have uncontrolled plasma C3 activation and spontaneously develop MPGN2 but not aHUS. We show that these mice, transgenically expressing a mouse FH protein functionally equivalent to aHUS-associated human FH mutants, regulate C3 activation in plasma and spontaneously develop aHUS but not MPGN2. These animals represent the fi rst model of aHUS and provide in vivo evidence that effective plasma C3 regulation and the defective control of complement activation on renal endothelium are the critical events in the molecular pathogenesis of FH-associated aHUS.
short consensus repeat (SCR) domains of the protein (13) , are frequently associated with normal C3 and FH levels, and result in defective binding of FH to heparin, C3b, and endothelium (14) (15) (16) (17) . Importantly, clustering of these mutations among carboxy-terminal domains would not be expected to alter plasma C3 regulation, because this function resides among the amino-terminal four SCR domains (17, 18) . Therefore, we hypothesized that FH-associated aHUS would require both eff ective plasma C3 regulation and defective regulation on renal endothelium.
RESULTS AND DISCUSSION
That MPGN2 and AMD, but not aHUS, have pathological similarities was recapitulated in the at-risk single nucleotide polymorphism (SNP; Table S1 , available at http://www.jem .org/cgi/content/full/jem.20070301/DC1) and haplotype ( Fig. 1 ) association data derived from a comparative genetic analysis, using a minimal set of informative CFH SNPs, in Spanish subjects with aHUS, AMD, and MPGN2. No overlapping between CFH aHUS-associated at-risk alleles or atrisk haplotypes was seen with the other conditions, consistent with previous data (19, 20) . CFH haplotype H1 (-332C, c.184G, c.1204C, c.2016A, and c.2808G) was signifi cantly increased in AMD and MPGN2 versus controls but not in aHUS patients. Conversely, haplotype H3 (-332T, c.184G, c.1204T, c.2016G, and c.2808T) was signifi cantly increased in aHUS patients but not in either AMD or MPGN2 patients. Notably, haplotype H2 (-332C, c.184A, c.1204T, c.2016A, and c.2808G), previously shown to protect from AMD (19) , was markedly decreased in all three conditions, suggesting that this haplotype may be associated with increased FH regulatory activity and reduced AP activation. A strong correlation between the CFH genotypes and the pathological outcome is further supported by the observation that the carboxy-terminal CFH mutations, frequently found in aHUS patients (2-5), were not detected in either healthy controls or subjects with MPGN2 or AMD (Table S2) . These genetic data support the hypothesis that distinct functional alterations in FH are critical in the pathogenesis of aHUS and AMD/MPGN2.
To test this hypothesis and to establish that a combination of eff ective plasma C3 regulation and defective regulation on renal endothelium is required for aHUS to develop, we generated transgenic mice expressing a mouse FH protein (FH∆16-20) that lacked the terminal fi ve SCR domains (Fig.  2 A) , the equivalent mouse location of the majority of aHUSassociated FH human mutations (13) . These animals were intercrossed with FH-defi cient (Cf h −/− ) mice to generate mice expressing either the mutant protein alone (Cf h −/− . or in combination with the full-length mouse protein (Cf h +/− .FH∆16 -20) . Cf h −/− .FH∆16-20 mice were viable, and FH∆16-20 was detectable in plasma ( Fig. 2 B) at levels comparable to FH in Cf h +/− mice (Fig. 2 C) . Analogous to aHUS-associated FH human mutants, FH∆16-20 retained complement regulatory activity but showed impaired binding to heparin and human umbilical vein endothelial cells (HUVECs) in vitro (Fig. 3) .
Cf h −/− mice have secondary plasma C3 depletion (12), enabling us to assess the ability of FH∆16-20 to regulate AP activation in vivo by measuring C3 levels in the Cf h −/− . FH∆16-20 mice. C3 levels were signifi cantly higher in the Figure 1 . Association analysis of CFH haplotypes with aHUS, AMD, and MPGN2 within a single population. Schematic illustration of the CFH exon structure demonstrating the location of the fi ve SNPs included in these studies. These SNPs represent a minimal informative set for genetic variation within the CFH gene. CFH haplotypes with a frequency >3% are shown. The frequency of each CFH haplotype was compared with the controls and the aHUS, AMD, and MPGN2 cohorts, and the p-values and the OR were calculated. Risk haplotypes are shaded red, whereas protective haplotypes are shaded in green.p-values were derived using the two-sided Fisher's exact test. OR and 95% confi dence interval (95% CI) are shown. See Table S1 for individual CFH SNP allele frequencies in patients with these conditions. The nucleotide and amino acid numbering refer to the translation start site (A in ATG is +1; Met is +1), as recommended by the Human Genome Variation Society.
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Cf h −/− .FH∆16-20 mice compared with Cf h −/− littermate controls (Fig. 4 A) . C3 levels in Cf h +/− .FH∆16-20 mice were also signifi cantly higher compared with age-matched Cf h +/− mice, reaching wild-type C3 levels (Fig. 4 A) . Thus, FH∆16-20 retained the ability to regulate plasma C3 activation in vivo. Spontaneous GBM C3 deposition is seen in Cf h −/− mice (12) . To assess the ability of FH∆16-20 to regulate C3 activation within the kidney, we compared glomerular C3 staining in 3-wk-old Cf h −/− .FH∆16-20, Cf h +/− . FH∆16-20, and Cf h −/− mice (Fig. 4 B) . In striking contrast (Fig. 5 A) . Endothelial damage characteristic of thrombotic microangiopathy was evident on ultrastructural examination of these animals ( Fig. 5 B) . Importantly, electron-dense GBM deposits, an ultrastructural feature of MPGN2 that we have previously shown to be present at this age in Cf h −/− mice (12) That a degree of plasma C3 regulation is required to enable thrombotic microangiopathy to develop derived from our observations in a second transgenic line (Cf h −/− .FH∆16-20low) with a median plasma FH∆16-20 level of only 2% of normal wild-type FH levels. Median plasma C3 levels were 34.8 mg/ liter (range = 20.7-50.1 mg/liter; n = 6), signifi cantly less than the median value measured in the Cf h −/− .FH∆16-20 mice (79.5 mg/liter; P < 0.001) but greater than median C3 ; n = 16), which were comparable to FH levels in Cf h +/− mice (median = 28.9%, range = 20.5-50.5%; n = 21; P > 0.05). In the Cf h +/− . FH∆16-20 mice, total FH levels were 64.5% (range = 46.7-84.6%; n = 18), signifi cantly higher than levels in either the Cf h −/− .FH∆16-20 (P < 0.001) or the Cf h +/− (P < 0.001) mice. Horizontal bars denote median values. *, P < 0.001 for Cf h +/− .FH∆16-20 mice versus all other groups using Bonferroni's multiple comparison test. levels in Cf h −/− animals (14.3 mg/liter; P < 0.01). At 8 mo of age, renal histology in the Cf h −/− .FH∆16-20low mice (n = 6) demonstrated only mild mesangial expansion with no evidence of thrombotic microangiopathy. Furthermore, these mice did not develop hematuria or red cell fragmentation, and serum urea levels remained normal at the time of death (median = 10.6 mmol/liter, range = 8.9-11.5 mmol/liter). Capillary wall C3 staining was reduced in comparison to age-matched Cf h −/− mice, and subendothelial electron-dense GBM deposits were infrequent. Hence, the plasma C3 regulation in the Cf h −/− . FH∆16-20low mice was insuffi cient for aHUS to develop but did prevent the development of MPGN2 up to the time point examined. The data from both transgenic lines, together with the observation that aHUS did not develop in Cf h −/− mice that have secondary C3 depletion, demonstrated that C3 activation is a key eff ector mechanism in aHUS.
There is now overwhelming evidence that aHUS is associated with defective regulation of the AP of complement activation. Mutations aff ecting the cofactors for the factor I-mediated proteolytic inactivation of activated C3 in plasma (FH; references 2-5, 21) and on cell surfaces (membrane cofactor protein; references 15, 22) , in addition to mutations aff ecting the serine protease factor I itself (23), predispose to the development of aHUS. Similarly, gain-of-function mutations in the complement activator factor B also predispose to aHUS, further supporting the critical role of C3 activation in the pathogenesis of aHUS (24) . The spontaneous pathology in the Cf h −/− .FH∆16-20 mice, like that of humans with functionally similar FH mutations, targeted the renal vasculature, suggesting that there are unique anatomical and/or physiological properties of this endothelial bed that render it particularly sensitive to complement-mediated damage.
Interestingly, aHUS-associated mutations in complement genes are normally found in heterozygosis in aHUS patients and are frequently associated with incomplete penetrance. In this respect, it is notable that Cf h +/− .FH∆16-20 mice did not spontaneously develop aHUS, suggesting that, like in some human patients, multiple genetic defects aff ecting complement regulators are required for aHUS to develop in mice (25, 26) . Furthermore, infection, immunosuppressive drugs, cancer therapies, oral contraceptive agents, pregnancy, or postpartum period are all factors that may trigger aHUS in individuals carrying CFH mutations in heterozygosis, and the syndrome has developed in the native kidney of live-related kidney donors who had previously unidentifi ed FH mutations (27) . Thus, Cf h +/− .FH∆16-20 mice may only develop aHUS after an additional insult, either genetic or environmental (or both), although interspecies diff erences in the regulation of C3 on cell surfaces by FH and other complement regulators may also be relevant to the apparent resistance of Cf h +/− .FH∆16-20 mice to aHUS.
Treatment of aHUS associated with FH mutations is diffi cult. Renal transplantation is associated with a high incidence of disease recurrence (28) . Plasma infusions as a source of FH have been benefi cial (29) but can result in hyperproteinemia, requiring plasma exchange (30) . The principle source of FH is hepatic, and hence, the expected defi nitive treatment would be combined liver and renal transplantation, which has produced mixed results (31) (32) (33) . Our data defi ne an important aspect of therapy. Agents that attempt to restore C3 regulation must critically achieve this on cell surfaces. Indeed, our observations suggest that restoration of fl uid-phase regulation alone may, by increasing the circulating plasma C3 levels, be deleterious.
In conclusion, the similarities between the surface recognition domains of mouse and human FH (34) enabled us to mutate mouse FH to functionally mimic aHUS-associated human FH mutations. Cf h −/− mice expressing this mutant FH protein spontaneously developed aHUS, not MPGN2. Our data provide the fi rst in vivo proof of principle evidence that FH mutations specifi cally impairing surface recognition can result in spontaneous aHUS and defi ne the molecular pathogenesis of aHUS-associated FH mutations.
MATERIALS AND METHODS
Patients. This study included three independent cohorts of Spanish patients, comprising 94 aHUS patients selected on the basis of a clinical history of HUS with nondiarrhea-associated origin, 79 patients >60 yr old with AMD who presented with advanced choroidal neovascularization and drusen in both eyes, and 15 MPGN2 patients. An independent cohort of 139 agematched healthy Spanish controls with no family history of AMD, aHUS, or MPGN2 was also used in these experiments. Genomic DNA was generated from peripheral blood leukocytes using standard procedures. All protocols included in these studies have been approved by national and/or local institutional review boards, and all subjects gave their informed consent.
Genotyping and statistical analyses.
A set of fi ve SNPs, representing a minimal informative set for genetic variation within the CFH gene, were genotyped in controls and in the aHUS, AMD, and MPGN2 cohorts on genomic DNA by allelic discrimination using probes (TaqMan; Applied Biosystems) and real-time PCR equipment (PE7700; Applied Biosystems), according to the manufacturer's specifi cations, or by automatic DNA sequencing of PCRderived amplicons in a sequencer (ABI 3730; Applied Biosystems) using a dye terminator cycle sequencing kit (Applied Biosystems). Sequences of CFH exons 22 and 23 were determined in all individual controls and patients using PCR-derived amplicons, as previously described (26) . The frequency of alleles 1 and 2 from each SNP was compared with controls and aHUS, AMD, and MPGN2 cohorts, and the p-values, odds ratios (ORs), and 95% confidence intervals were calculated. Haplotype frequencies in the control and patient cohorts were estimated using the expectation maximization algorithm implemented by the SNPStats software (available at http://bioinfo.iconcologia .net/SNPstats). Nonparametric data were given as the median, with the range of values in parentheses, as indicated in the fi gures. We used the Mann-Whitney test to compare two groups and Bonferroni's multiple comparison test for the analysis of three groups. Data were analyzed by Prism software (version 3.00 for Windows; GraphPad Software).
Mice. Cf h −/− mice were generated as previously described (12) . To generate the FH∆16-20 protein, the codon encoding Cys937 at the beginning of SCR16 of mouse FH was substituted by a stop codon in the full-length cDNA clone using site-directed mutagenesis (QuickChange; Stratagene). A modifi ed version of the pCAGGS plasmid (35) bearing the CMV-EI enhancer, the chicken β-actin promoter, and intron 1 and the simian virus 40 poly(A) signal was used to construct the FH∆16-20-encoding transgene. The construct was excised from the vector by digestion with Kpn I and Sal I and purifi ed using a gel extraction kit (QIAEX II; QIAGEN), followed by Elutip purifi cation (Schleicher and Schuell). The DNA was injected into fertilized CBA × C57BL/6 F1 mouse eggs, and these were transplanted into 
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foster females. Progeny were screened for transgene integration by PCR, and expression of the mutant FH protein was determined by Western blotting. Heterozygous and homozygous FH-defi cient mice expressing the transgene were generated by intercrossing the transgenic animals with Cf h −/− mice. The presence of the transgene was detected by PCR using genomic DNA and oligonucleotides located within exon 5 (mHF1-4F, 5′-G C A A T T C A G G C T T C A A-G A T T G -3′), exon 9 (mHF1-8F, 5′-G A C A T G T A C A G A G A A T G G C T G -3′), and exon 13 (mHF1-6R, 5′-C C C A T T A A G A A T T T C A A G A G G T G -3′) of the mouse FH exonic sequence. The genotyping of the Cf h −/− mouse has been previously described (12) . All animal procedures were done in accordance with institutional guidelines.
Measurement of FH and C3 levels and Western blotting of plasma FH. FH levels were measured by ELISA using a goat anti-rat FH antibody (a gift from M. Daha, Leiden University Medical Center, Leiden, Netherlands) and a rabbit anti-mouse FH antibody. Samples were quantifi ed by reference to a standard curve generated using normal wild-type mouse serum. C3 levels were measured by ELISA using a goat anti-mouse C3 antibody (MP Biomedicals). Results were quantifi ed by reference to a standard curve generated from acute-phase sera containing a known quantity of C3 (Calbiochem). Mouse FH was detected by the Western blotting of serum with a cross-reactive polyclonal rabbit antibody against rat FH.
Heparin binding assay and cofactor activity. 200 μl EDTA plasma from a Cf h −/+ .FH∆16-20 mouse was dialyzed against 20 mM Tris-HCl (pH 7.4), 35 mM NaCl and applied to a heparin-sepharose column (HiTrap Heparin HP; GE Healthcare). After extensive washes, the proteins bound to the column were eluted with a NaCl linear gradient (35-250 mM). Two protein peaks containing FH were identifi ed by ELISA, and the eluted FH proteins were characterized by Western blot analysis. For the cofactor assay, we thank R.B. Sim (University of Oxford, Oxford, UK) for providing purifi ed human factor I.
Histological studies. For light microscopy, kidneys were fi xed in Bouin's solution and embedded in paraffi n, and sections were stained with periodic acid Schiff reagent. For immunofl uorescence studies, kidneys were snap frozen. FITC-conjugated goat antibody against mouse C3 (MP Biomedicals) and FITC-conjugated goat antibody against mouse IgG (Sigma-Aldrich) were used on snap-frozen sections. Mouse endothelium was stained using a rat antimouse CD31 (platelet/endothelial cell adhesion molecule 1) antibody (a gift from B. Imhof, University of Geneva, Geneva, Switzerland), followed by application of Texas red goat polyclonal anti-rat IgG antibody (Abcam). For electron microscopy, samples were fi xed in 3% glutaraldehyde, postfi xed in 2% aqueous osmium tetroxide, and embedded in Spurr's resin. Ultrathin sections were stained with 1% aqueous uranyl acetate and Reynold's lead citrate.
Assessment of renal function and hematological parameters. We measured serum urea using a UV method kit (R-Biopharm Rhone Ltd.) according to the manufacturer's instructions. Urinalysis was performed using Hema-Combistix (Bayer). Platelets were quantifi ed manually. In brief, whole blood was diluted 1:20 with 1% ammonium oxalate, and the suspension was mixed for 15 min to allow red cell lysis to occur. Samples were transferred to a hemocytometer (Bright-Line; Sigma-Aldrich), and platelets were directly counted. Blood fi lms were manually prepared using EDTA whole blood and stained using a rapid staining kit (Diff -Quik; Dade Behring).
Online supplemental material. Table S1 shows the frequencies of CFH polymorphisms in individuals with MPGN2, aHUS, and AMD. Table S2 shows the frequency of mutations in CFH exons 22 and 23 in controls and individuals with MPGN2, aHUS, and AMD. Table S3 shows We are grateful to all patients and the collaborating clinicians for their participation in this study. We thank Mr. Ian Shore for his technical assistance with the preparation of tissue for electron microscopy, Mrs. Margarita Lewis for technical assistance with the processing of histological specimens, and the staff of the Biological Services Unit at Imperial College for the care of the animals involved in this study. We also thank the members of the DNA sequencing laboratory at the Centro de Investigaciones Biologicas, as well as Dr. Elena Aller and Ms. Sheila Pinto for invaluable technical assistance with patient genotyping.
